LTR PHARMA LIMITED (ASX: LTP)
Health care · News and insights
Price unavailable
Latest LTP announcements
Announcement Insights
LTR Pharma Begins US ROXUS Prescriptions As SPONTAN Advances Toward Phase III
LTR Pharma has moved from clinical development toward initial US commercial activity, fulfilling its first patient-specific ROXUS prescriptions after quarter-end through telehealth and pharmacy agreements. A final Phase II report confirmed SPONTAN’s six-fold faster absorption than oral vardenafil and completed its FDA pharmacokinetic dataset, with Phase III targeted for the first half of 2027. The company also secured an Indian patent for SPONTAN and ROXUS formulations, extending protection to May 2041 subject to maintenance requirements and continued validity.
Updated 10 Nov 2026, 10:48 PM Sydney time
Sources
LTR Secures Indian Patent Supporting SPONTAN and ROXUSNick Bell Joins LTR Pharma as Strategic AdviserQuarterly Activities/Appendix 4C Cash Flow ReportComments
2026-11-09 · Health care
LTP: $0.455 +8.33% · MC: $86M
LTR Pharma has secured an Indian patent covering defined formulation characteristics of the nasal spray technology behind its SPONTAN and ROXUS erectile dysfunction treatments. Protection extends to May 2041, subject to maintenance requirements and continued validity. The company recently reported that the first ROXUS prescriptions had been fulfilled in the US and that more than 2,000 bottles of SPONTAN had been dispensed in Australia.
Updated 2026-11-09 10:24
Sources
LTR Secures Indian Patent Supporting SPONTAN and ROXUSComments
2026-11-04 · Health care
LTP: $0.410 +0.00% · MC: $86M
LTR Pharma has appointed entrepreneur Nick Bell as a strategic adviser, with an initial focus on introductions to telehealth platforms, clinic networks and commercial partners. He will also help evaluate scalable, compliant patient-access pathways for SPONTAN and KYZATREX in Australia; the appointment is intended to strengthen the company’s digital-health and commercial capabilities.
Updated 2026-11-04 08:40
Sources
Nick Bell Joins LTR Pharma as Strategic AdviserComments
2026-10-28 · Health care
LTP: $0.440 +0.00% · MC: $86M
LTR Pharma says its first patient-specific ROXUS prescriptions were fulfilled in the US after quarter-end, following agreements with telehealth platform Shed and Strive Pharmacy. A final Phase II report confirmed SPONTAN’s six-fold faster absorption than oral vardenafil tablets and completed its FDA pharmacokinetic dataset; a Phase III study is targeted to start in the first half of 2027. The company reported approximately A$18 million in cash and no debt at quarter-end, with net operating cash outflow of approximately A$2 million.
Updated 2026-10-28 08:26
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportComments
Comments